BriaCell Awarded New Zealand Patent for its Whole Cell Technology

PHILADELPHIA and VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, today announces that it has been granted New Zealand Patent No. 785587 titled “WHOLE-CELL CANCER VACCINES AND METHODS FOR SELECTION THEREOF”. The patent covers methods of selecting its whole-cell cancer immunotherapy technology for subjects with cancer based on HLA allele profile matching, providing exclusivity through February 27, 2037, and supporting BriaCell’s precision medicine approach aimed at personalizing immunotherapy for improved patient outcomes.

Read more at globenewswire.com